Novo Nordisk remains a strong investment due to its robust innovation and diverse drug pipeline, despite recent share price weakness. The company reported 10% sales growth, $5 billion in free cash flow, and a 4.8% dividend yield in 2025, supporting both dividends and share buybacks. While competition in GLP-1 drugs is increasing, international growth and market expansion offset U.S. market share losses, maintaining revenue strength. With a low single-digit price-to-earnings ratio, new drug developments, and a 7.5% shareholder yield, Novo Nordisk is well-positioned for sustainable returns despite patent and competitive risks.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
